Peter Rios

Peter Rios

Auto-generated profile, based on publicly available information

Peter Rios

CellTrans Inc., Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Science Advances
Verified
Journal Article
Open access
ANAmanda M. Nash
Amanda M. Nash
MJMaria I. Jarvis
Maria I. Jarvis
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
Sudip MukherjeeSudip Mukherjee
Sudip Mukherjee
AHAndrea Hernandez
Andrea Hernandez
OVOmid Veiseh
Omid Veiseh
Proinflammatory cytokines have been approved by the Food and Drug Administration for the treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects that limit long-term benefits. To overcome these limitations, we developed a clinically translatable cytokine delivery platform composed of polymer-encapsulated human ARPE-19 (RPE) cells that produce natural cytokines. Tumor-adjacent administration of these capsules demonstrated predictable dose modulation with spatial and temporal control and enabled peritoneal cancer immunotherapy without systemic toxicities. Interleukin-2 (IL2)–producing cytokine factory treatment eradicated peritoneal tumors in ovarian and colorectal mouse models. Furthermore, computational pharmacokinetic modeling predicts clinical translatability to humans. Notably, this platform elicited T cell responses in NHPs, consistent with reported biomarkers of treatment efficacy without toxicity. Combined, our findings demonstrate the safety and efficacy of IL2 cytokine factories in preclinical animal models and provide rationale for future clinical testing in humans.

7 June 2024 in Science Advances
Verified
Journal Article
Open access
JBJacqueline A. Burke
Jacqueline A. Burke
YZYunxiao Zhu
Yunxiao Zhu
XZXiaomin Zhang
Xiaomin Zhang
PRPeter D. Rios
Peter D. Rios
IJIra Joshi
Ira Joshi
GAGuillermo A. Ameer
Guillermo A. Ameer
Clinical outcomes for total-pancreatectomy followed by intraportal islet autotransplantation (TP-IAT) to treat chronic pancreatitis (CP) are suboptimal due to pancreas inflammation, oxidative stress during islet isolation, and harsh engraftment conditions in the liver’s vasculature. We describe a thermoresponsive, antioxidant macromolecule poly(polyethylene glycol citrate- co - N -isopropylacrylamide) (PPCN) to protect islet redox status and function and to enable extrahepatic omentum islet engraftment. PPCN solution transitions from a liquid to a hydrogel at body temperature. Islets entrapped in PPCN and exposed to oxidative stress remain functional and support long-term euglycemia, in contrast to islets entrapped in a plasma-thrombin biologic scaffold. In the nonhuman primate (NHP) omentum, PPCN is well-tolerated and mostly resorbed without fibrosis at 3 months after implantation. In NHPs, autologous omentum islet transplantation using PPCN restores normoglycemia with minimal exogenous insulin requirements for >100 days. This preclinical study supports TP-IAT with PPCN in patients with CP and highlights antioxidant properties as a mechanism for islet function preservation.

28 January 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
MBMatthew A. Bochenek
Matthew A. Bochenek
SFShady Farah
Shady Farah
JDJoshua Doloff
Joshua Doloff
HHHye Jung Han
Hye Jung Han
ASAtieh Sadraei
Atieh Sadraei
DADaniel G. Anderson
Daniel G. Anderson
Immunoisolation devices containing therapeutic protein-secreting cells offer potential for long-term therapy without immune suppression. However, scar tissue formation driven by the foreign body response (FBR) hinders nutritional exchange and ultimately leads to graft failure. We previously showed that inhibiting the colony-stimulating factor-1 receptor (CSF1R) pathway in monocytes and macrophages can block the FBR to implanted materials. Here, we demonstrate that coencapsulation of slow-releasing CSF1R inhibitor (GW2580) crystals with human stem cell–derived β cells (SC-β) in alginate spheres enables stable glycemic control for 1 year in immune-competent diabetic C57BL/6 mice. In nonhuman primates (NHPs), GW2580 crystals similarly protected viable, glucose-responsive allogeneic β cells for 1 month without systemic immune suppression. In contrast, the same xenogeneic human SC-β cell formulation that functioned long-term in mice elicited extensive sphere overgrowth and graft failure in NHPs. Serum cytokine profiling and transcriptomic analysis of omental biopsies at day 30 revealed pronounced adaptive immune activation in xenogeneic recipients, including enrichment of CD4 + T cells, CD19 + B cells, and antigen-presenting cell programs marked by elevated MHC class II expression. Chemokines CCL17 , CCL22 , and CXCL13 were among the most highly up-regulated transcripts, mirroring responses observed previously with profibrotic alginate formulations without cells. These findings underscore the issues associated with xenogeneic cell sources in higher-order species yet indicate that targeting innate immune pathways with localized CSF1R inhibition may be sufficient to enable function of encapsulated allogeneic cell therapies.

12 June 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HCHelen D. Clark
Helen D. Clark
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
JSJake Schladenhauffen
Jake Schladenhauffen
JDJonathon Debonis
Jonathon Debonis
JAJuan Carlos Amador-Molina
Juan Carlos Amador-Molina
SWShannon N. Westin
Shannon N. Westin
Purpose: Platinum-resistant high-grade serous ovarian carcinomas (HGSOC) are associated with poor therapeutic outcomes. Although HGSOC frequently metastasizes to the intraperitoneal (IP) cavity, the success of IP cytokine therapies, such as IL2, has been hampered by local toxicity and administration difficulties. AVB-001 is a novel IL2 delivery system consisting of encapsulated, allogeneic cells engineered for constitutive human IL2 (hIL2) expression. Patients and Methods: This is a phase I dose-escalation trial of AVB-001 for the treatment of HGSOC (NCT05538624). A single dose of AVB-001 was administered by IP laparoscopy, enabling hIL2 doses from 0.6 to 3.6 μg hIL2/kg/day. Safety was evaluated using NCI Common Terminology Criteria for Adverse Events v5.0. Efficacy was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immunotherapy RECIST criteria. Results: The trial enrolled 14 patients across four dose levels. Three (21.4%) patients experienced grade 3 treatment-related adverse events (TRAE); no grade 4 to 5 TRAEs were reported. There was one dose-limiting toxicity. There was one unconfirmed partial response but no confirmed responses (overall response rate 0%). Stable disease was observed in seven patients, with a median duration of 2.57 months (range, 2.03–4.23). The clinical benefit rate was 14.3% (n = 2). Pharmacokinetics demonstrated dose-dependent increases in serum IL2, peaking at 1 day after implantation. Immunologic analyses revealed sustained CD8+ and CD4+ T-cell proliferation without corresponding proliferation in regulatory T cells. Dose-dependent CTLA-4 receptor upregulation was observed on CD8+ and CD4+ T cells, whereas PD-1 and TIM-3 remained unchanged. Conclusions: In patients with HGSOC, AVB-001 is safe and effectively activates cytotoxic T cells, supporting further investigation of this locoregional immunotherapy.

7 August 2026 in Science Advances
Verified
Journal Article
Open access
BKBoram Kim
Boram Kim
DVDilrasbonu Vohidova
Dilrasbonu Vohidova
ANAmanda Nash
Amanda Nash
YCYuen San Chan
Yuen San Chan
SFSamantha Fleury
Samantha Fleury
OVOmid Veiseh
Omid Veiseh
The efficacy of cell-based therapeutics is often compromised by host immune recognition of implanted cells and biomaterials, resulting in fibrotic encapsulation and loss of function. Here, we address this challenge with an immunomodulatory cell-based therapy, in which alginate-encapsulated retinal pigment epithelial cells continuously secrete cytokines to locally modulate the implant microenvironment. In a healthy rodent model, the localized production of interleukin-10 (IL-10) or IL-12 from encapsulated cytokine-producing cells prevented foreign body response to alginate capsules. Mechanistically, treatment was associated with reduced expression of profibrotic genes and immune shifts consistent with macrophage and T cell regulation, supporting a cytokine-mediated mitigation of foreign body response. In a diabetic murine model (streptozotocin-induced C57BL/6J), coimplantation of human islets with IL-10–producing cells attenuated pericapsular fibrosis, preserved islet viability, and restored normoglycemia for up to 100 days (4.76 times longer than islets alone). Notably, IL-10–producing cells were also effective in enabling the durability and function of encapsulated cells in a healthy nonhuman primate, showing translational feasibility. Collectively, these findings suggest that localized cytokine delivery can reduce fibrotic encapsulation and support durable graft function, offering a path to lessen reliance on systemic immunosuppression in islets transplantation and other implantable biomaterial therapies.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
ANAmanda Nash
Amanda Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
AHAndrea Hernandez
Andrea Hernandez
SGSofia Ghani
Sofia Ghani
IJIra Joshi
Ira Joshi
OVOmid Veiseh
Omid Veiseh
Background Pancreatic cancer is often diagnosed at advanced stages and responds poorly to chemotherapy.1 Because high tumor T cell infiltration corresponds with better clinical outcomes in pancreatic cancer patients, immunotherapy has gained significant interest for treatment. IL-12 is a proinflammatory cytokine that activates CD8+ T cells and NK cells.2 Unfortunately, systemic high dose IL-12 administration led to severe toxicities in clinical trials which limited further development of this cytokine as a cancer therapeutic. To address this limitation, we developed an implantable cytokine delivery platform for local administration of IL-12. These cytokine factories, composed of genetically engineered cells encapsulated in biocompatible polymers, allow for safe and controlled dosing in vivo. Cytokine PK Studies Supernatant from individual capsules were assayed at 1-, 2-, 4-, or 24-hours using ELISA (n=6). Mouse Studies For IP tumors, 1e6 pan02 cells were injected in the IP space of mice. Cytokine factories were implanted 7 days post tumor injection. Primate Studies Cytokine factories were administered to cynomolgus macaques (n=1). Complete blood count and blood chemistry analysis were performed for 28 days after administration. IVIS Imaging Mice were injected in the IP space with D-luciferin (300 µg/mL, PerkinElmer). Photographs and luminescent images were acquired 10 minutes after injection. Results Local administration of IL-12-based cytokine factories caused reduction of pan02 tumor burden by 80% after 1 week of treatment in mice (figure 1). Single cell RNAseq of the tumor adjacent immune cells showed 2x more T cells in IL-12 treated mice than untreated mice suggesting immune cell infiltration. Importantly, the IL-12 dose was well tolerated in all mice for 180 days. In efforts to evaluate the translatability of this platform, we further tested IL-12-based cytokine factories in a non-human primate. The cytokine factories produced a high local IL-12 concentration without substantial leakage into the systemic circulation and were well tolerated by the primates as shown by the lack of fever or weight loss, as well as the lack of renal or liver toxicity. Conclusions Our findings highlight the therapeutic potential of IL-12 treatments when administered locally via cytokine factories in preclinical animal models. Further, these findings provide rationale for future clinical testing of cytokine factories in a wide range of metastatic cancers in humans. References Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, Mahmoud MM, Warsi MK, Rasool M, Jamal M.S, Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int 2018;2018: 9056173. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response. Semin Oncol 2006;33:583–587. IL-12 cytokine factories reduce mice pancreatic tumor burden a) Total flux calculated from IVIS imaging prior to treatment with RPE-mIL2, RPE-mIL12, RPE only, or untreated (n=5). b) Representative IVIS images of each treatment group 5 days post treatment.